Seeking Alpha

ImmunoGen forges co-operation agreement with CytomXs

  • ImmunoGen (IMGN) forms a partnership with CytomXs Therapeutics to develop Probody-drug conjugate therapies for the treatment of cancer.
  • The co-operation brings together ImmunoGen's ADC technology for targeting cancer cells with CytomXs's Probody antibodies, which are designed to remain inert in healthy tissue but be activated in diseased cells. (PR)
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio: